Effect of Drugs on Colonic Eicosanoid Accumulation in Active Ulcerative Colitis

References

• Kirsner J D, Shorter RG. Recent developments in nonspecific inflammatory bowel disease. N Engl J Med 1982; 306: 775–85; 837–48
   PubMed Web of Science ®Google Scholar
• MacDermott R P, Stenson WF. The role of the immune system in inflammatory bowel disease. Immunol Allerg Clin N Am 1988; 8: 3
   Google Scholar
• MacDermott R P, Stenson WF. Alterations of the immune system in ulcerative colitis and Crohn's disease. Advanc Immunol 1988; 42: 285–328
   PubMed Web of Science ®Google Scholar
• Parker CW. Mediators: release and function. Fundamental immunology, WE Paul. Raven Press, New York 1984; 697–750
   Google Scholar
• Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75: 638–40
   PubMed Web of Science ®Google Scholar
• Gould S R, Brash A R, Conolly ME. Increased prostaglandin production in ulcerative colitis. Lancet 1977; 2: 98
   PubMedGoogle Scholar
• Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 453–60
   PubMed Web of Science ®Google Scholar
• Eliakim R, Karmeli F, Razin E, Rachmilewitz D. Role of platelet activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology 1988; 95: 1167–72
   PubMed Web of Science ®Google Scholar
• Ligumsky M, Simon P L, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel discase-enhanced production during active disease. Gut 1990; 31: 686–9
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Masden J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1988; 91: 83744
   Google Scholar
• Peskar B M, Dreyling K W, Peskar B A, May B, Goebell H. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions 1986; 18: 381–3
   PubMedGoogle Scholar
• Present D H, Korelitz B I, Wisch N, Glass J L, Sacher D B, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long term, randomized, double-blind study. N Engl J Med 1980; 302: 981–7
   PubMed Web of Science ®Google Scholar
• Korelitz B J, Present DH. Favorablc cffect of 6-mercaptopurinc on fistulas of Crohn's disease. Dig Dis Sci 1985; 30: 58–64
   PubMed Web of Science ®Google Scholar
• Brynskov J, Freund L, Rasmussen S N. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Mcd 1989; 321: 845–50
   PubMed Web of Science ®Google Scholar
• Kozarek R A, Patterson D T, Gelfand M D, Botoman V A, Ball T J, Wilske KR. Methotrexate induces clinical and histologic remission in paticnts with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353–6
   PubMed Web of Science ®Google Scholar
• Schroeder K W, Tremaine W J, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625–9
   PubMed Web of Science ®Google Scholar
• Meyers S, Sachar D B, Present D H, Janowitz I-ID. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987; 93: 1255–62
   PubMed Web of Science ®Google Scholar
• Peppercorn MA. Advances in drug therapy for inflammatory bowcl disease. Ann Intern Med 1990; 112: 50–60
   PubMed Web of Science ®Google Scholar
• Buckcll N A, Gould S R, Day D W, Lennard-Jones J E, Edwards AM. Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis. Gut 1978; 19: 1140–3
   PubMedGoogle Scholar
• Dronfield M W, Langman MJ. Comparative trial of sulfasalazine and oral sodium cromoglycate in thc maintenance of remission in ulcerative colitis. Gut 1978; 19: 1136–9
   PubMedGoogle Scholar
• Grace R H, Gent A E, Hellier MD. Comparative trial of sodium cromoglycate enemas with prednisolone enemas in the treatment of ulcerative colitis. Gut 1987; 28: 88–92
   PubMedGoogle Scholar
• Mayer L, Sachar DB. Efficacy of chloroquine in the treatment of inflammatory bowel disease [abstract]. Gastroenterology 1988; 94: A293
   Web of Science ®Google Scholar
• Eliakim R, Karmeli F, Okon E, Rachmilewitz D. Ketotifen effectively prevents mucosal damage in experimental colitis. Gut, In press
   Google Scholar
• Karmeli F, Eliakim R, Okon E, Rachmilewitz D. Gastric mucosal damage is mediated by substance P and prevented by ketotifen, a mast cell stabilizer. Gastroenterology 1991; 100: 1206–16
   PubMedGoogle Scholar
• Bauminger S, Zor U, Linder HR. Radioimmunological assay of prostaglandin synthetase activity. Prostaglandins 1973; 4: 313–24
   PubMed Web of Science ®Google Scholar
• Lysy J, Karmeli F, Wengrower D, Rachmilewitz D. Effect of duodenal ulcer healing induced by omeprazole and ranitidine on the generation of gastroduodenal eicosanoids, platelet-activating factor, pepsinogen A, and gastrin in duodenal ulcer patients. Scand J Gastroenterol 1992; 27: 13–9
   PubMed Web of Science ®Google Scholar
• Sharon P, Stenson WF. Metabolism of arachidonic acid in acetic acid colitis in rats: similarity to human inflammatory bowel disease. Gastroenterology 1985; 88: 55–63
   PubMed Web of Science ®Google Scholar
• Wallace J L, MacNaughton W K, Morris G P, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989; 96: 29–36
   PubMed Web of Science ®Google Scholar
• Lewis R A, Austen KF. The biologically active leukotrienes. Biosynthesis function and pharmacology. J Clin Invest 1984; 73: 889–97
   PubMed Web of Science ®Google Scholar
• Granger D N, Grisham M B, Zimmerman B J, Von Ritter C. Reactive oxygen metabolites as mediators in cell injury in the intestine. Inflammatory bowel disease: current status and future approach, RP MacDermott. Elsevier Scientific Publishers, New York 1988; 255–60
   Google Scholar
• Wallace J L, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 1990; 258: G529–34
   Google Scholar
• Present DH. Cyclosporine in inflammatory bowel disease. Inflammatory bowel disease 1990, D Rachmilewitz, J. Zimmerman. Kluwer Academic Publishers, Amsterdam 1990; 243–54
   Google Scholar
• Kozarek RA. Use of methotrexate for refractory inflammatory bowel disease. Inflammatory bowel disease 1990, D Rachmilewitz, J Zimmerman. Kluwer Academic Publishers, Amsterdam 1990; 255–65
   Google Scholar
• Bernard A, Dondrifosse G, Romain N, Forget P. Effect of methotrexate on the intestinal mucosa of PGE2 treated rats. Life Sci 1989; 45: 2591–603
   PubMedGoogle Scholar
• Pieniaszek H J, Bates TR. Capacity-limited gut wall metabolism of 5-aminosalicylic acid; a therapeutically active metabolite of sulphasalazine in rats. J Pharm Sci 1979; 68: 1323–5
   PubMed Web of Science ®Google Scholar
• Allgayer H, Ahnfelt N O, Kruis W. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989; 97: 38–41
   PubMed Web of Science ®Google Scholar
• Ireland A, Priddle J D, Jewell DP. Acetylation of S-aminosalicylic acid by isolated human colonic epithelial cells. Clin Sci 1990; 78: 105–11
   PubMed Web of Science ®Google Scholar
• Van Hogezend R A, Van Hees P AM, Van Gorp J PWM. Double-blind comparison of 5-aminosalicylic acid and acetyl 5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther 1988; 2: 33–40
   Google Scholar
• Meese C O, Fischer C, Klotz U. Is N-acetylation of S-aminosalicylic acid reversible in man. Br J Clin Pharmacol 1984; 18: 612–5
   PubMedGoogle Scholar
• Nielsen O H, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal installation in man. Br J Clin Pharmacol 1983; 16: 738–40
   PubMed Web of Science ®Google Scholar
• Ireland A, Jewell DP. Sulphasalazine and the new salicylates. Eur J Gastroenterol Hepatol 1989; 1: 11421
   Google Scholar
• Myers B, Evans D NW, Rhodes J. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196–200
   PubMed Web of Science ®Google Scholar
• Klotz U. Clinical pharmacokinetics of sulphasalazine its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 1985; 10: 285–302
   PubMed Web of Science ®Google Scholar
• McLeod R S, Cohen Z, Vari B J, Blair J E, Greenberg GR. The release profile of a controlled release preparation of 5-aminosalicylic acid (Rawasa I) in humans. Colon Rectum 1990; 33: 21–5
   PubMedGoogle Scholar
• Willoughby C P, Piris J, Truelove SC. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol 1980; 15: 715–9
   PubMed Web of Science ®Google Scholar
• Peskar B M, Dreyling K W, May B, Schaarschmidt K, Goebell H. Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci 1987; 32: 51S–6S
   Google Scholar
• Nielsen O H, Bukhave K, Elmgreen J, Ahnfelt-Ronne I. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1987; 32: 577–82
   PubMed Web of Science ®Google Scholar